Montefiore Medical Center (Moses Campus)

The Bronx, NY

Sorting 9 by

Not yet accepting

ELRiSE MDS

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
  • Activin Receptor IIA Inhibitor
  • Randomization
  • Phase 3

Accepting patients

Eganelisib

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
  • PI3K Inhibitor
  • Randomization
  • Phase 1

Accepting patients

Tetrahydrouridine + Decitabine

Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes
  • Cytidine Deaminase Inhibitor
  • Phase 1

Accepting patients

Danvatirsen Plus Venetoclax

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
  • BCL-2 Inhibitor
  • Antisense Oligonucleotide (ASO)
  • Phase 1

Not currently accepting

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
  • Phase 1/2

Accepting patients

AK117/Placebo with Azacitidine

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
  • Monoclonal Antibody
  • CD47
  • Closed Label (Masked)
  • Randomization
  • Placebo
  • Phase 2

Accepting patients

Low Dose Weekly Decitabine/Venetoclax

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

SX-682

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
  • CXCR1 Inhibitor
  • CXCR2 Inhibitor
  • Phase 1
  • Has results